Benjamin Chen, MD, PhD, of the Icahn School of Medicine at Mount Sinai, discusses the implications of his new study involving genetically tagging immune cells with latent HIV.
Benjamin K. Chen, MD, PhD, professor in the Division of Infectious Diseases, Department of Medicine in the Icahn School of Medicine at Mount Sinai, spoke about the results of his recently published study, which found that researchers could genetically tag immune cells with latent HIV. Chen was the senior author on the study published in Nature Communications.
This transcript was lightly edited; captions were auto-generated.
Transcript
Can you explain the result of your study on genetically tagging immune cells with HIV?
Yeah, my pleasure. HIV causes a chronic infection for which we have great antiretroviral drugs. But presently, the virus is still incurable, and that's because the virus has the ability to lay dormant in very rare cells in the immune system and even in a treated patient. These cells are exceedingly rare to isolate and study in patients. We've figured out a way to develop a genetically modified mouse with human cells in it, which allows us to use a genetic switch technology to detect those very, very rare latent cells so we can enrich them greatly. We've studied their genetic properties in great detail, giving us insights into what makes those latent cells unique.
How can genetically tagging cells with HIV potentially change treatment for HIV moving forward?
With the technology that we've used in these humanized mice—these mice with human immune systems—we can isolate lots of these cells. With those cells, we've done something, used a technology called single cell sequencing, and identified single cell genetic signatures that are occurring more frequently in these latent cells as compared to the nonlatent cells. We have an opportunity here to think of ways to use this knowledge to maybe reverse the patterns which enforce latency. The whole idea is to reawaken cells which are latent, so that the immune system, or with additional therapies, we could affect the cure potentially and eliminate the latent reservoir.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More